Introduction
Throughout the history of the world, the ones who had confronted the bitterest face of poverty and war had always been the women. As known poverty and war affects human health either directly or indirectly, the effects of this condition on health and status of women in the society should not be ignored. This study intends to cast light on the effects of war and poverty on the reproductive health of women. For this purpose, the face of war affecting the women, the problem of immigration, inequalities in distribution of income based on gender and the effects of all these on the reproductive health of women will be addressed.
War and Women's Health
Famine, synonymous with war and poverty, is clearer for women; war means deep disadvantages such as full destruction, loss of future and uncertainty for women. Wars are conflicts that destroy families, societies and cultures that negatively affect the health of community and cause violation of human rights. According to the data of World Health Organization (WHO) and World Bank, in 2002 wars had been among the first ten reasons which killed the most and caused disabilities. Civil losses are at the rate of 90% within all losses (1) . War has many negative effects on human health. One of these is its effect of shortening the average human life. According to the data of WHO, the average human life is 68.1 years for males and 72.7 years for females. It is being thought that severe military conflicts in Africa shorten the expected lifetime for more than 2 years. In general, WHO had calculated that 269 thousand people had died in 1999 due to the effect of wars and that loss of 8.44 million healthy years of life had occurred (2, 3) . Wars negatively affect the provision of health services. Health institutions such as hospitals, laboratories and health centers are direct targets of war. Moreover, the wars cause the migration of qualified health employees, and thus the health services hitches. Assessments made indicate that the effect of destruction in the infrastructure of health continues for 5-10 years even after the finalization of conflicts (3). Due to resource requirements in the restructuring investments after war, the share allocated to health has decreased (1).
Mortalities and Morbidities
The ones who are most affected from wars are women and children. While deaths depending on direct violence affect the male population, the indirect deaths kill children, women and elders more. In Iraq between 1990-1994, infant deaths had shown this reality in its more bare form with an increase of 600% (4). The war taking five years increases the child deaths under age of 5 by 13%. Also 47% of all the refugees in the world and 50% of asylum seekers and displaced people are women and girls and 44% refugees and asylum seekers are children under the age of 18 (5) .
As the result of wars and armed conflicts, women are
Abstract
War and poverty are 'extraordinary conditions created by human intervention' and 'preventable public health problems. ' War and poverty have many negative effects on human health, especially women's health. Health problems arising due to war and poverty are being observed as sexual abuse and rape, all kinds of violence and subsequent gynecologic and obstetrics problems with physiological and psychological courses, and pregnancies as the result of undesired but forced or obliged marriages and even rapes. Certainly, unjust treatment such as being unable to gain footing on the land it is lived (asylum seeker, refugee, etc.) and being deprived of social security, citizenship rights and human rights brings about the deprivation of access to health services and of provision of service intended for gynecology and obstetrics. 
Study Population
The study population consisted of women aged 18-40 years, who were eligible for IUD insertion according to the state protocol. After IUD insertion, only women who had more than 7 days of menstrual bleeding or menstrual blood volume of greater than 80 mL were included in the study. The type of IUD used was TCu380A. Women were excluded from the study if they had a history of anatomical abnormalities such as uterine myoma; adenomyosis; coagulopathy, such as thromboembolism or stroke; anticoagulant therapy; drug sensitivity; gastrointestinal bleeding; genital infection; endometritis; and other confounding factors that can lead to increased bleeding. All subjects had a history of regular spontaneous menstrual cycles (cycle length: 24-35 days).
Method
The method of blood loss volume calculation was instructed to all participants during the first visit. Pictures of bloody sanitary pads smeary to 10, 20, 30, and 40 mL blood were shown to them. Patients were asked to keep a daily record of the number of sanitary pads used and group them according to the pictures of pads that were lightly (10 mL), mildly (20 mL), moderately (30 mL), or completely (40 mL) saturated (3) . If the total score was more than 80 mL points per menstrual cycle, it was an indication of a greater than 80 mL blood loss. Participants were placed in either the tranexamic acid (120 subjects) or the mefenamic acid group (90 subjects). Of the 6 health centres, 3 were randomly allocated to provide the patients with tranexamic acid and the other 3 were assigned to provide them with mefenamic acid. The number of women who referred to the first 3 health centres (tranexamic acid group) and were eligible to participate in the study was incidentally higher compared to the other 3 health centres (mefenamic acid group). The first group took two 250 mg capsules of tranexamic acid 3 times a day, and the second group took two 250 mg capsules of mefenamic acid (Ruz Darou, batch no. L-15) 3 times a day. Each group continued taking the capsules for 3-5 days based on the duration of bleeding. Investigators were blinded of the intervention. The intervention for using the drugs during haemorrhage took 3 months. The questionnaire forms were filled out before the treatment as well as every month for 3 months. Our primary outcome measures were days of menstruation, volume of blood loss, and the sequence of bleeding. Secondary outcome measure was haemoglobin (Hb) concentration on admission and at the end of the treatment.
Statistical Analysis Paired sample t test was used to compare the numerical variables of the 2 groups and t test was used for the 2 independent samples. For ordinal data, non-parametric Mann-Whitney test was employed and chi-squared test was performed to compare the categorical data. Moreover, for analysing the trend of bleeding reduction over time, the repeated measures analysis of covariance (ANCOVA) was used, with adjustment for baseline bleeding. P value of <0.05 was considered significant. All analysis was performed using the SPSS software (version 16).
Results
The total number of women enrolled in this study was 210, with 120 women in group 1 (tranexamic acid) and 90 women in group 2 (mefenamic acid). There were no significant differences between the mean age, number of pregnancies and deliveries, educational status (Table  1) , and previous contraception methods (Table 2 ) of the 2 groups according to t test and chi-squared analysis.
Baseline mean blood loss in the 2 groups was significantly different, which is incidental in different centres. Baseline Hb was not significantly different between the 2 groups (Table 1) . Mean menstrual days in both group 1 and group 2 decreased significantly (from 10.22 to 3.58 days in group 1 and from 12.33 to 4.63 days in group 2); this reduction was progressive during the 3 months of the treatment. The P value was < 0.05 in both groups according to independent samples t test (Table 3) . These decreases were 64% in group 1 and 62% in group 2 and the difference between the groups was not significant based on chi-squared analysis (Table 4) . In group 1, the volume of bleeding decreased by 23.43% after the first month (P < 0.001) and by 14.28% after the second month of the treatment (P = 0.001); mean blood loss decreased significantly (by 42.3%) compared to mean baseline bleeding after 3 months, from 256.57 ml to 160.61 mL (P < 0.001) ( Table 5 , Figure 1 ). In group 2, the volume of bleeding decreased by 24.14% after the first month (P < 0.001), but not progressively after the second month of the treatment; mean blood loss decreased significantly compared to mean baseline bleeding after 3 months, from 170.31 mL to 96.35 l mL (P < 0.001) ( Table 5 , Figure 1 ).
The reduction in mean blood loss at the end of the threemonth treatment was not significantly different between the 2 groups according to repeated measures ANCOVA (adjusted for baseline); rate of decrease was 42.3% in group 1 and 44.5% in group 2 (P = 0.15) ( Table 4 ). The Hb concentration after the three-month treatment was not significantly different between the 2 groups (P = 0.12). Sixty-three women in group 1 (52.5%) and 53 women in group 2 (58.8%) withdrew from the group before completion of the study. In group 1, reasons behind withdrawals included improvement in condition (26 subjects); removal of the IUD (14 subjects); withdrawal of consent (11 subjects); inability to adhere to the visit schedule (11 subjects); and ineffectiveness of the medication (1 subject). In group 2, reasons for discontinuation were: improvement in condition (18 subjects); removal of the IUD (18 subjects); withdrawal of consent (5 subjects); inability to adhere to the visit schedule (5 subjects); ineffectiveness of the medication (3 subjects); incorrect intake of the study medication (2 subjects); side effects (1 subject); and personal reasons (1 subject). Removal of the IUD during the study was higher in group 2; 20% of women in group 2 removed their IUD compared to only 11.67% in group 1 (Figure 2) . Their difference, however, was not significant based on chisquared analysis (P = 0.36).
Discussion

Findings and Interpretation
At the beginning of the study, 210 women, who met the inclusion criteria, were enrolled in the study with 120 subjects in group 1 and 90 subjects in group 2. However, during the study, which occurred over a span of 3 months, some women withdrew, with the causes being: improvement in condition, removal of the IUD, side effects, inability to adhere to the visit schedule, withdrawal of consent, incorrect intake of the study medication, personal reasons, and ineffectiveness of the medication. Fourteen subjects in the tranexamic acid group and 17 subjects in the mefenamic acid group (total = 31) withdrew from the study at the end of the first month. Moreover, 35 subjects from the tranexamic acid group (total = 63) and 18 subjects from the mefenamic acid group (total = 53) withdrew from the study at the end of the second month. After the 3-month treatment, 57 subjects in the tranexamic acid group and 37 subjects in the mefenamic acid group had completed the study and statistical analysis was done on all 94 cases (Figure 2 ). The number of women who withdrew from the study in the mefenamic acid group was more than the tranexamic acid group. This may be partly due to the difference in the rate of satisfaction and efficacy of the drugs. Mean days of bleeding decreased significantly in both groups, by 64% in the tranexamic acid group and by 62% in the mefenamic acid group.
In the tranexamic acid group, the volume of bleeding decreased progressively after the first and second months (by 23.45 and 14.3%, respectively). However, the decrease in the third month, in relation to the second month, was not significant. Reduction of bleeding in relation to baseline bleeding after the second and the third months (by 39.5 and 42.3%, respectively) was significant (P < 0.001).
In the mefenamic acid group, the volume of bleeding decreased significantly after the first month (by 24.4%), but not significantly in subsequent months. The reduction in bleeding in relation to baseline after the second and the third months (by 36.6 and 44.5%, respectively) was significant (P < 0.001). These results indicate that the peak effect of both drugs was at the end of the second month. Others, % 0 5.9
a P = 0.36
Strengths and Weaknesses of the Study
One of the strengths of this study was that the method of calculation of blood loss was instructed to each participant at the first visit. Therefore, all the clients and investigators had a uniform definition of the qualitative variable (i.e. the volume of blood loss) in the study. Furthermore, the participants in each treatment arm were monitored for 3 cycles, which allowed for a more precise evaluation and comparison of the efficacy of the administered drugs.
As is the case in most longitudinal studies, some participants decided to not continue with the treatment during the course of the study, though in most cases (38%), it was due to the fact that their condition had improved. This resulted in a decrease in our sample size. Moreover, blinding was not possible with the patients and care providers, since tranexamic acid and mefenamic acid were supplied as tablets in the original blister pack.
Differences in Results and Conclusions
In a systematic review by Godfery et al, evidence suggests that intranasal desmopressin, tranexamic acid, or NSAIDs may be effective in treatment of bleeding irregularities; however, these treatments were only studied in a small number of patients and their safety has not been welldocumented. According to Godfery et al, "Level I to II-1, fair to poor" evidence suggests that tranexamic acid and NSAIDs may prevent menorrhagia in Cu-IUD users, although "Level I, good" evidence suggests that NSAID use may not influence continuation of the Cu-IUD. The number of women who participated in these case studies were small and either the dosage of the drugs was high (tranexamic acid 1.5 g three times daily) or the drugs were administered for a long duration, such as for 7-10 days of the cycle during 6-7 cycles (2). In a review study by Wellington and Wagstaff, tranexamic acid resulted in a greater reduction in bleeding (a 56% decrease) compared to diclofenac sodium (a 24% decrease) and placebo (a 5% decrease). However, neither tranexamic acid nor diclofenac sodium had any significant effects on the duration of menses. The dosage of tranexamic acid was 1.5 g three times daily for 5 days (9). In Coulter et al study, efficacy of NSAIDs and tranexamic acid were compared; volume of bleeding decreased by 29% and 47%, respectively. The dosage of the drugs in this study was 500 mg for mefenamic acid and 1-24 g for tranexamic acid (10) . In Bonnar and Sheppard study, 3 drugs were compared: mefenamic acid, tranexamic acid, and ethamsylate. The rate of bleeding reduction was 20% and 54% for the first 2 drugs, respectively, but the third one had no significant effects. The dosage of the drugs in this study was 500 mg for mefenamic acid and 1 g for tranexamic acid, administered four times daily for 5 days during 3 cycles (11). However, in our study, the dosage was 500 mg three times daily for 3-5 days. In Ylikorkala and Viinikka study, tranexamic acid reduced the mean blood loss by 54% and diclofenac sodium resulted in a decrease of 20%. The dosage of tranexamic acid was 1.5 g three times daily for 5 days during 2 cycles (7).
In Kaviani et al study, tranexamic acid was more effective than mefenamic acid for reduction of bleeding days as well as the volume of bleeding. Moreover, tranexamic acid had a quicker effect compared to mefenamic acid. The sample size of this case study was small (total = 58) and the dosage of the drugs was smaller in comparison with our study: 250 mg three times daily for 3 days during 2 months (12). In Yavarikia et al study, the effect of mefenamic acid and vitagnus in reducing IUD-induced bleeding were compared. The effect of the 2 drugs was approximately the same after 4 months and in the mefenamic acid group, bleeding was reduced by 52%. The dosage and duration of mefenamic acid use was 250 mg three times daily for 8 days during 4 months (13).
In Najam et al study, the effects of a combination of tranexamic acid and mefenamic acid were compared with the effects of tranexamic acid alone. The combination drug reduced the bleeding by 59.3% and tranexamic acid alone reduced the bleeding by 50%. The dosage of drugs in this study was 500 g tranexamic acid plus 250 mg mefenamic acid for the combination group, and 500 mg for the tranexamic group, administered 3 times daily for 5 days during 3 cycles. Improvement in Hb was observed after 6 months (14) .
In our study, both drugs had the same effect on reducing the days of bleeding as well as the volume of bleeding. The difference between the results of our study compared to the other studies may be due to the difference in the dosage of the administered drugs and the duration of the treatment.
Relevance of the findings: Implications for Clinicians and Policymakers IUD is a prevalent method of contraception. Accordingly, in order to improve its satisfaction level, we recommend that public health clinics administer these two drugs to their clients. Moreover, we suggest that the causes of discontinuation of IUD in clients be evaluated before and after the intervention.
Unanswered Questions and Future Research
The study aimed to compare the efficacy of tranexamic acid and mefenamic acid on reducing the duration of menstruation and volume of blood loss, as well as to evaluate their effect on the sequence of bleeding in TCu380A IUD users. During the course of the study, there were a number of participants who withdrew from the trial and discontinued their use of IUD. To gain a better understanding of the effect of the two administered drugs, further studies are therefore needed to evaluate the reasoning behind discontinuation of IUD.
Conclusion
Our results suggest that both drugs, tranexamic acid as an anti-fibrinolytic agent, and mefenamic acid as an NSAID, at dosage of 500 mg three times daily for 3-5 days during 3 months have the same significant effects on Copper T-380A IUD-induced menorrhagia. Their effects are on both the volume of blood loss and the duration of menses. The peak effects of both drugs are at the end of the second month and the effect of tranexamic acid is more progressive. Comparison with other studies indicated that the dosage and the duration of treatment are important factors that influence the rate at which the drugs exert their effects.
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